Related Experiment Video
Updated: May 24, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Clofarabine in pediatric acute leukemia: current findings and issues
Nobuko Hijiya1, Elly Barry, Robert J Arceci
1Northwestern University Feinberg School of Medicine and Division of Pediatric Hematology-Oncology, Children's Memorial Hospital, Chicago, Illinois 60614-3394, USA. nhijiya@childrensmemorial.org
Pediatric Blood & Cancer
|February 23, 2012
Summary
Clofarabine shows anti-leukemic activity and is FDA-approved for pediatric acute lymphoblastic leukemia (ALL). Combination therapies are being explored for improved efficacy and understanding their roles and toxicities in treating ALL is crucial.
Area of Science:
- Oncology
- Pharmacology
Background:
- Clofarabine is a purine nucleoside analog with established anti-leukemic properties.
- It is FDA-approved for pediatric relapsed or refractory acute lymphoblastic leukemia (ALL).
Purpose of the Study:
- To review the development of clofarabine.
- To examine the rationale and history of clofarabine combination regimens.
- To discuss the potential roles and toxicities of these combinations in pediatric ALL treatment.
Main Methods:
- Literature review of clofarabine development.
- Analysis of studies investigating clofarabine combination therapies.
- Evaluation of clinical data on efficacy and toxicity.
Main Results:
- Clofarabine demonstrates significant single-agent anti-leukemic activity.
- Combination regimens with clofarabine are under investigation for synergistic effects.
- Frontline studies are evaluating these combinations in pediatric ALL.
Conclusions:
- Combination therapies involving clofarabine are being explored to enhance treatment outcomes in pediatric ALL.
- Understanding the roles and toxicities of these regimens is vital for clinicians.
- Further research is needed to optimize clofarabine-based combination strategies.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...